Skip 
Navigation Link

1215 South Walnut Ave.
Demopolis, AL 36732 map map 

Access to Care: 800.239.2901

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Health Tip: If You're 45 or Older, Get Screened for Colorectal CancerRed Cross Issues Nationwide Call for Blood DonationsDoctor Burnout Widespread, Helps Drive Many Medical ErrorsWarming Climate, More AC -- and More Unhealthy Smog AheadEven at 'Safe' Levels, Air Pollution May Boost Diabetes RiskDeath Certificate Data May Miss Many Opioid ODs: StudyRaise the Bar on CPR, Heart Group SaysWhen DEA Cracked Down on Opioids, Abusers Moved to Black Market: StudyStigma of Safe Needle Exchanges Lingers Despite Opioid EpidemicAHA: Drones a Lifesaver for Cardiac Arrest Patients?Millions Die Worldwide Each Year for Lack of Quality CareTips for Handling a Medical EmergencyAHA: Lifesaving Info Not Always a 911 Call AwayMany, But Not All, Hospitals Require Flu Shots for StaffersCancer Care Twice as Costly in U.S. Versus CanadaAHA: Health Concerns Haunt Puerto Rico as New Hurricane Season BeginsPot, Opioids Now Rival Alcohol as Factor in Driver DeathsThe ER or Urgent Care?Trumps Signs Bill Allowing Terminal Patients to Try Unproven MedicinesTough State Drunk Driving Laws Save LivesE-Cigarettes Don't Help Smokers Quit, But Cash MightSmall World? Not With One-Quarter Obese by 2045A Pill to Protect You From the Sun? Don't Believe It, FDA SaysMost Hospitals Aren't Ready for Mass Tragedies, ER Docs SayAHA: Making America's Doctors Look More Like AmericaLanguage Used in Medical Record Can Affect Patient CareNonprofit Manufacturer Could Keep Generic Drug Costs DownOpioid Makers' Perks to Docs Tied to More PrescriptionsFDA Targets Clinics Offering Unapproved Stem Cell TherapiesLittle 'Quit-Smoking' Help at U.S. Mental Health CentersIs Testing for Zika in U.S. Blood Supply Worth the Cost?'Smoke-Free' Rooms Still Loaded With Smoke Residues, Study FindsAHA: Smoke-Free Laws Do Seem to Help Young Adults' HeartsAHA: Poverty Levels Key to States' Performance on Heart DiseaseSimple Drug Packaging Change Could Save Toddlers' LivesFDA Cracks Down on Dangerous E-Cig Liquids That Resemble Cookies, CandyNew Clinic Satisfaction Tool Provides Real-Time FeedbackUnused Meds? Saturday Is National Drug Take Back DayA Doctor's Age May Matter With Emergency SurgeryPatients Prefer Doctors Who Engage in Face-to-Face VisitsU.S. Better Able to Tackle Health Emergencies: ReportFirst Opioid Lawsuit Targeting Pharmacy Benefit ManagersMost Doctors' Offices Don't Offer Flexibility for UninsuredSafety Info for Opioids Found LackingNonoptimized Drug Therapy Costs More Than $500 Billion AnnuallyFDA Cracks Down on Caffeine-Loaded SupplementsCigarette Tax Hike Could Ease Poverty for Millions Worldwide: StudyCDC: Aggressive Action Needed to Contain Antibiotic ResistanceCould Medical Pot Help Curb the Opioid Abuse Crisis?Medical E-Records Not Without Risks: Study
Questions and AnswersVideosLinksBook Reviews
Related Topics

Health Insurance
Healthcare

FDA Seeks to Speed Development of 'Regenerated' Organs for Medical Use

HealthDay News
by -- E.J. Mundell
Updated: Nov 16th 2017

new article illustration

THURSDAY, Nov. 16, 2017 (HealthDay News) -- Using stem cells to grow new heart tissue, and even whole organs, used to be the stuff of science fiction.

But the field of "regenerative medicine" is a reality now -- and the U.S. Food and Drug Administration has its eye on it, the agency's head said Thursday.

"In the last decade, we've seen improbable advances that hold out great hope for patients," FDA Commissioner Dr. Scott Gottlieb said in an agency news release. "I believe that with the ability to facilitate the regeneration of parts of the human body, we're bearing witness to the beginning of a paradigm shift in the practice of medicine."

For example, over the past few years scientists and physicians have developed tissue-engineered skin for transplant; bladders grown from a patient's own cells; and tissues grown to repair ailing hearts or failing knees, according to the U.S. National Institutes of Health.

But Gottlieb said that along with all this good comes the bad. Companies seeking to exploit consumers are already popping up across the United States -- stem cell "clinics" promising pricey cures that they can't deliver to desperate patients.

"The rapid growth and promise of this field has increasingly sowed the ground for the entry of some unscrupulous actors, who have opportunistically seized on the clinical potential of regenerative medicine to make deceptive claims to patients about unproven and, in some cases, dangerous products," Gottlieb said.

"By exploiting the lack of consumer understanding of this area, as well as the fear and uncertainties posed by the diseases these bad actors claim to treat, they're jeopardizing the legitimacy and advancement of the entire field," he explained.

So, Gottlieb says his agency is rolling out a new "regulatory framework" aimed at encouraging and speeding legitimate development of regenerative therapies that do work, while stamping out firms offering bogus treatments.

He said the FDA intends to promote the "least burdensome" rules for companies big and small that are seeking to develop new therapies, "while ensuring patient safety."

"Our policy will allow product manufacturers that time to engage with the FDA to determine if they need to submit a marketing authorization application and, if so, seek guidance on how to submit their application to the FDA for approval," Gottlieb said.

The new rules are in keeping with provisions from the 21st Century Cures Act, passed by Congress in December. That legislation earmarked $6.3 billion in funding, mostly for the U.S. National Institutes of Health, towards groundbreaking medical research.

According to Gottlieb, the bottom line is to allow patients "access to safe and effective regenerative medicine products as efficiently as possible. We are also committed to making sure we take action against products being unlawfully marketed that pose a potential significant risk to their safety."

More information

There's more on regenerative medicine at the U.S. National Institutes of Health.